HTB | HIV i-Base

HTB

New double issue: reports from AIDS 2020, plus COVID-19 research with UK studies and new treatments...

Featured HTB: no. 9 – HIV and COVID-19: issue 6 (22 July 2020) 22 July 2020. Related: Editorial.
Featured i-Base appeal: please support i-Base with £5 or £10 a month 22 July 2020. Related: Editorial.
Featured HIV and COVID-19: issue 4 (1 June 2020) 1 June 2020. Related: Editorial.
Featured HIV and COVID-19: issue 3 (14 May 2020) 14 May 2020. Related: Editorial, COVID-19.
Featured HTB 17 April 2020: CROI 2020 and COVID-19 supplement 17 April 2020. Related: Editorial.
Featured HTB 27 March 2020: CoV-2 and COVID-2019 special edition 27 March 2020. Related: Editorial, COVID-19.
Featured Impact of isolation and loneliness on older people living with HIV 13 December 2019. Related: Conference reports, Ageing and life expectancy, HIV and Ageing 2019.
Featured The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk 1 October 2017. Related: Special reports, HIV prevention and transmission.
HIV associated with worse outcomes from hospitalised COVID-19 in UK 12 August 2020. Related: Early access, COVID-19: HIV and COVID-19 coinfection, COVID-19.
US FDA approves dolutegravir/lamivudine (Dovato) as switch option 7 August 2020. Related: Early access, Antiretrovirals.
ViiV resubmits cabotegravir plus rilpivirine long-acting injections (Cabenuva) to FDA for approval 6 August 2020. Related: Early access, Antiretrovirals.
European and UK doctors review latest studies on HIV and COVID-19 coinfection 5 August 2020. Related: Early access, COVID-19: HIV and COVID-19 coinfection, COVID-19.
IAS COVID-19 Conference: introduction 22 July 2020. Related: Conference reports, Conference index, IAS COVID-19 virtual 2020.
Conference opening and making sense of the science 22 July 2020. Related: Conference reports, COVID-19, IAS COVID-19 virtual 2020.
HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality 22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19, IAS COVID-19 virtual 2020.
Predictors of response to remdesivir in GS-5773 COVID-19 study 22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19, IAS COVID-19 virtual 2020.
AIDS 2020 online: introduction 22 July 2020. Related: Conference reports, Conference index, World AIDS 23 Virtual 2020.
AIDS 2020: Navigating the website 22 July 2020. Related: Conference reports, World AIDS 23 Virtual 2020.
Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study 22 July 2020. Related: Conference reports, Pregnancy, World AIDS 23 Virtual 2020.
Dolutegravir associated with weight gain in African ART programmes: findings from AFRICOS 22 July 2020. Related: Conference reports, Side effects, World AIDS 23 Virtual 2020.
ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau 22 July 2020. Related: Conference reports, Antiretrovirals, World AIDS 23 Virtual 2020.
Obesity linked to dolutegravir, especially with TAF, could increase risk of adverse pregnancy outcomes 22 July 2020. Related: Conference reports, Women's health, Pregnancy, Side effects.
Pregnancy meta-analysis: dolutegravir- versus efavirenz-based ART 22 July 2020. Related: Conference reports, Pregnancy, World AIDS 23 Virtual 2020.
Long-acting cabotegravir injections are effective as HIV PrEP in gay men and transgender women: results from HPTN 083 22 July 2020. Related: Conference reports, HIV prevention and transmission, World AIDS 23 Virtual 2020.
Case report of short-term HIV remission from adding oral nicotinamide to intensified ART 22 July 2020. Related: Conference reports, Cure research, World AIDS 23 Virtual 2020.
New HIV remission case report at AIDS 2020: full report 22 July 2020. Related: Conference reports, Cure research, World AIDS 23 Virtual 2020.
FDA approves fostemsavir (Rukobia) for multidrug resistant HIV in the US 22 July 2020. Related: Antiretrovirals.
UK government cuts HIV PrEP budget in England by a third 22 July 2020. Related: HIV prevention and transmission.
BHIVA virtual conference: Best of CROI and COVID-19 update 22 July 2020. Related: On the web.
Access and procurement to ARVs in the Russian federation 22 July 2020. Related: On the web.
Pneumocystis Jirovecii Pneumonia (PJP) mistaken for COVID-19 in late stage undiagnosed: urgency of including HIV testing on admission 22 July 2020. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
NYC cohort reports similar outcomes from COVID-19 in HIV positive vs HIV negative adults 22 July 2020. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
Spanish study reports associations between COVID-19 and HIV treatment including NRTIs 22 July 2020. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
UK study reports inhaled interferon-Beta reduces time to recovery from COVID-19 22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Review of COVID-19 in people with immune suppression 22 July 2020. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
EMA grants conditional approval for remdesivir in the EU to treat COVID-19 22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Drug price announced for remdesivir – as US buys up world stock 22 July 2020. Related: COVID-19: treatment access, COVID-19.
RECOVERY study reports that lopinavir/r fails to show benefit against COVID-19 22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Hydroxychloroquine and lopinavir/r arms stopped in the WHO SOLIDARITY study 22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Individualising management of COVID-19 based on real-time inflammatory responses 22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Further positive reports from tocilizumab to treat COVID-19 22 July 2020. Related: COVID-19: investigational drugs, COVID-19.
Higher mortality from COVID-19 in London study in Asian or Black compared to white participants 22 July 2020. Related: COVID-19: pathogenesis, COVID-19.
UK study reports antibody responses linked to more severe COVID-19 in higher risk populations 22 July 2020. Related: COVID-19: pathogenesis, COVID-19.
Leading SARS-CoV-2 antibody tests meet specificity but fail current sensitivity guidelines 22 July 2020. Related: COVID-19: diagnostics, COVID-19.
Infectious SARS-CoV-2 in air and on surfaces in London hospitals 22 July 2020. Related: COVID-19: transmission & prevention, COVID-19.
US prisoners have higher mortality rates from COVID-19 22 July 2020. Related: COVID-19: transmission & prevention, COVID-19.
US SARS-CoV-2 epidemic could see 100,000 cases per day: NIAID head Anthony Fauci to Senate hearing 22 July 2020. Related: COVID-19: transmission & prevention, COVID-19.
Research during COVID-19 22 July 2020. Related: COVID-19: research studies, COVID-19: on the web, COVID-19.
Vaccine candidates report phase 3 studies after early safety and immune responses in phase 1/2 studies 22 July 2020. Related: COVID-19: vaccine, COVID-19.
FDA guidance on COVID-19 vaccine includes minimal target of 50% efficacy 22 July 2020. Related: COVID-19: vaccine, COVID-19.
Future meetings 2020/21 22 July 2020. Related: Future meetings.
HTB no 9 – plus: HIV and COVID-19 bulletin no 6 (22 July 2020) 22 July 2020. Related: PDFs.
HIV and COVID-19: issue 5 (26 June 2020) (HTB no 8) 26 June 2020. Related: Editorial.
23rd International AIDS Conference (AIDS 2020) 26 June 2020. Related: Conference reports.
FDA approves dolutegravir formulations to treat infants and young children 26 June 2020. Related: Antiretrovirals, Paediatric care.
Latest studies on HIV/COVID-19 coinfection 26 June 2020. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.